Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
äŒæ¥ã³ãŒãCMMB
äŒç€ŸåChemomab Therapeutics Ltd
äžå Žæ¥Aug 14, 2012
æé«çµå¶è²¬ä»»è
ãCEOãMor (Adi)
åŸæ¥å¡æ°16
蚌åžçš®é¡Depository Receipt
æ±ºç®ææ«Aug 14
æ¬ç€Ÿæåšå°Kiryat Atidim, Building 7
éœåžTEL AVIV-YAFO
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœIsrael
éµäŸ¿çªå·6158002
é»è©±çªå·972773310156
ãŠã§ããµã€ãhttps://www.chemomab.com/
äŒæ¥ã³ãŒãCMMB
äžå Žæ¥Aug 14, 2012
æé«çµå¶è²¬ä»»è
ãCEOãMor (Adi)